Show simple item record

dc.contributor.authorMacleod, Angus D
dc.contributor.authorDalen, Ingvild
dc.contributor.authorTysnes, Ole-Bjørn
dc.contributor.authorLarsen, Jan Petter
dc.contributor.authorCounsell, Carl E
dc.date.accessioned2018-02-01T14:28:07Z
dc.date.available2018-02-01T14:28:07Z
dc.date.issued2018-01
dc.identifier.citationMacleod , A D , Dalen , I , Tysnes , O-B , Larsen , J P & Counsell , C E 2018 , ' Development and validation of prognostic survival models in newly diagnosed Parkinson’s disease ' Movement Disorders , vol. 33 , no. 1 , pp. 108-116 . DOI: 10.1002/mds.27177en
dc.identifier.issn0885-3185
dc.identifier.otherPURE: 107331495
dc.identifier.otherPURE UUID: beff90f6-ee3c-45be-9244-78e9bb6235c8
dc.identifier.otherPubMed: 28976022
dc.identifier.otherPubMed: 28976022
dc.identifier.otherScopus: 85040677583
dc.identifier.urihttp://hdl.handle.net/2164/9977
dc.descriptionAcknowledgments We would like to thank study participants, study personnel, and study funders. Funding agencies: The Parkinsonism Incidence in North-East Scotland (PINE) study was supported by Parkinson's UK (Grants G-0502, G-0914, G-1302), the Scottish Chief Scientist Office (CAF 12/05), the British Medical Association (BMA) Doris Hillier award, RS Macdonald Trust, the Bupa Foundation, National Health Service (NHS) Grampian endowments, NHS R&D, and SPRING. The ParkWest study was supported by the Research Council of Norway (Grant 177966), the Western Norway Regional Health Authority (Grants 911218 and 911949), and the Norwegian Parkinson's Disease Association.en
dc.format.extent9en
dc.language.isoeng
dc.relation.ispartofMovement Disordersen
dc.rightsThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. https://creativecommons.org/licenses/by/4.0/en
dc.subjectJournal Articleen
dc.subjectParkinson's diseaseen
dc.subjectprognosisen
dc.subjectmortalityen
dc.subjectdependencyen
dc.subjectRC0321 Neuroscience. Biological psychiatry. Neuropsychiatryen
dc.subjectParkinson's UKen
dc.subjectG-0502en
dc.subjectG-0914en
dc.subjectG-1302en
dc.subjectChief Scientist Office (CSO)en
dc.subjectCAF 12/05en
dc.subject.lccRC0321en
dc.titleDevelopment and validation of prognostic survival models in newly diagnosed Parkinson’s diseaseen
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen, Other Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen, Chronic Disease Research Groupen
dc.contributor.institutionUniversity of Aberdeen, Data Safe Havenen
dc.contributor.institutionUniversity of Aberdeen, Institute of Applied Health Sciencesen
dc.description.statusPeer revieweden
dc.description.versionPublisher PDFen
dc.identifier.doihttps://doi.org/10.1002/mds.27177


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record